ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Medical Genetics, PhD Medical Genetics

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,945Medicare Part D Prescriptions Filled, Including Refills
$435K Total Retail Price of All Prescriptions
314 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
81% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
HYDROCODONE-ACETAMINOPHEN 451 403 S3
FUROSEMIDE 374 365
POTASSIUM CHLORIDE 365 355
WARFARIN SODIUM 352 338
LEVOTHYROXINE SODIUM 338 307
OMEPRAZOLE 229 188
LISINOPRIL 205 186
DONEPEZIL HCL 168 167
MIRTAZAPINE 137 133
NAMENDA 135 135
CITALOPRAM HBR 127 120
QUETIAPINE FUMARATE 116 91
HYDROCHLOROTHIAZIDE 108 98
LANTUS 106 84
SEROQUEL 103 95
METOPROLOL TARTRATE 98 78
OLANZAPINE 97 49
CYMBALTA 97 82
SIMVASTATIN 91 72
RANITIDINE HCL 91 91
AMLODIPINE BESYLATE 84 82
TRAZODONE HCL 84 67
GABAPENTIN 81 77
CARBIDOPA-LEVODOPA 81 71
CARVEDILOL 79 79
OXYCODONE-ACETAMINOPHEN 75 73 S2
METFORMIN HCL 74 51
POLYETHYLENE GLYCOL 3350 74 65
SERTRALINE HCL 74 73
DIVALPROEX SODIUM 70 37
ALLOPURINOL 66 57
BACLOFEN 64 29
ALENDRONATE SODIUM 63 62
LEVETIRACETAM 61 42
RISPERIDONE 59 33
NYSTATIN 56 48
METOPROLOL SUCCINATE 56 54
ATENOLOL 54 45
FLUOXETINE HCL 50 48
PHENYTOIN SODIUM EXTENDED 50 47
TAMSULOSIN HCL 50 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 24, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.